Articles tagged "Immunosuppression"

2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
J. Klepacki,¹ J. Klawitter,¹ J. Klawitter,¹ A. Karimpour-fard,² E. Anderson,¹ G. Ingle,³ D. Patel,³ K. Johnson,⁴ D. Cibrik,⁴ U. Christians.¹
¹University of Colorado Denver, Aurora, CO; ²University of Colorado Denver, Aurora, CO; ³Novartis Pharmaceuticals, East Hannover, NJ; ⁴University of Michigan, Ann Arbor, MI.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…
2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
M. Bakir, N. Jackson, E. Chang, D. Henriquez-Ticas, C.-H. Tseng, T. Khuu, J. Zhang, E. Reed, M. Deng, M. Cadeiras.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…
2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
K. Unagami,¹ M. Okumi,² M. Furusawa,² T. Hirai,² T. Shimizu,² K. Omoto,² M. Inui,² H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…
2016 American Transplant Congress
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.
K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Gronthos,⁴ S. Grey,⁵ P. Coates.^1,2,3
¹School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ²Centre for Clinical and Experimental Transplantation, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ³Centre for Stem Cell Research and Robinson Institute, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia; ⁴Mesenchymal Stem Cell Laboratory, School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ⁵Transplant Immunology Group, Garvin Institute of Medical Research, Sydney, New South Wales, Australia.
Human bone marrow derived MSC-17 are superior T cell immunomodulators for allotransplantation. Untreated-MSC (UT-MSC) or 5 days IFNγ (MSCγ) or IL-17A (MSC-17) treated MSC were…
2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
A. Karim, D. Conway, G. Leverson, J. Mezrich, L. Fernandez, A. D'Alessandro, D. Foley.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…
2016 American Transplant Congress
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.
A. Bushell,¹ J. van der Net,^1,2 D. Game,³ R. Hilton,³ S. Thirkell,⁴ P. Friend,² E. Geissler,⁵ K. Wood,¹ P. Harden,² G. Lombardi.⁴
¹Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; ²Oxford Transplant Centre, Oxford, United Kingdom; ³Guy's Hospital, London, United Kingdom; ⁴Immunoregulation Laboratory, King's College London, Guy's Hospital, London, United Kingdom; ⁵Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Introduction: The UK ONE Study trial investigates the safety and feasibility of regulatory T (Treg) cell therapy in renal transplantation.Materials and Methods: Eleven (9m;2f) living…
2016 American Transplant Congress
Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.
M. van der Giet,¹ J. de Fijter,¹ F. Oppenheimer,¹ L. Toselli,¹ G. Russ,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ H. Holdaas.¹
¹ELEVATE study group, Berlin, Germany; ²Novartis pharma AG, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover, NJ.
Background: Immunosuppressive therapies are probably the most important cause of hyperlipidemia post-renal transplantation (RTx). Lipid abnormalities represent important biomarkers for cardiovascular (CV) risk. Here, we…
2016 American Transplant Congress
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.
M. Carmellini,¹ P. Todeschini,² A. Secchi,³ S. Sandrini,⁴ E. Minetti,⁵ L. Furian,⁶ G. Spagnoletti,⁷ F. Pisani,⁸ G. Piredda,⁹ G. Cappelli,¹⁰ G. Tisone.¹¹
¹AOU Senese, Siena, Italy; ²AOP S.Orsola-Malpighi, Bologna, Italy; ³Osp San Raffaele IRCCS, Milano, Italy; ⁴AO Spedali Civili, Brescia, Italy; ⁵AOU Careggi, Firenze, Italy; ⁶AOU di Padova, Padova, Italy; ⁷PU A.Gemelli, Roma, Italy; ⁸POU S.Salvatore, L'Aquila, Italy; ⁹AO G.Brotzu, Cagliari, Italy; ¹⁰AOUP di Modena, Modena, Italy; ¹¹Fondazione PU Tor Vergata, Roma, Italy.
The NEVERWOUND study was designed to evaluate the impact of immediate vs. delayed introduction of everolimus (EVR) on wound healing complications (WHC) and delayed graft…
2016 American Transplant Congress
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.
A. Chandraker, J. Kobashigawa, J. Stehlik, M. Givertz, R. Pierson, S. Pinney, M. Joren, S. Nissen, I. Guleria, Y. Morrison, B. Armstrong, N. Bridges, M. Sayegh, R. Starling.
On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.
PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…
2016 American Transplant Congress
Learning from Cancer: Using D-Lactate for Therapeutic Immunosuppression.
U. Beier,¹ J. Jiao,¹ H. Xiao,¹ A. Angelin,² D. Wallace,² M. Levine,³ W. Hancock.⁴
¹Pediatric Nephrology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; ²Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA; ³Department of Surgery, University of Pennsylvania, Philadelphia, PA; ⁴Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Univerisity of Pennsylvania, Philadelphia, PA.
Accumulation of lactic acid in the tumor microenvironment contributes to local immunosuppressive conditions that weaken anti-tumor immunity. Lactic acid exists as L- and D- optical…